Aptevo Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-26.0M | $-24.1M | $-17.4M | $8.0M | $-28.5M | $-17.8M | $-40.4M | $-53.7M |
| Depreciation & Amortization | $240.0K | $352.0K | $567.0K | $901.0K | $1.1M | $1.4M | $2.2M | $2.4M |
| Depreciation | $200.0K | $400.0K | $600.0K | $900.0K | $1.1M | $1.2M | $1.4M | $1.6M |
| Amortization | — | — | — | — | — | — | $800.0K | $800.0K |
| Stock-Based Compensation | $96.0K | $1.1M | $2.2M | $1.8M | $1.6M | $1.3M | $1.6M | $2.1M |
| Net Cash from Operating Activities | $-25.6M | $-23.8M | $-11.7M | $-21.0M | $-21.7M | $-29.3M | $-42.4M | $-51.4M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | $29.0K | $713.0K | $88.0K | $153.0K | $976.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $0 | $0 | $-29.0K | $-713.0K | $28.0M | $4.1M | $72.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $38.5M | $15.6M | $6.0M | $-2.6M | $26.2M | $23.9M | $20.1M | $-787.0K |
| Net Change in Cash | $12.9M | $-8.2M | $-5.7M | $-23.7M | $3.8M | $22.6M | $-18.1M | $20.6M |
| Free Cash Flow | — | — | — | $-21.1M | $-22.4M | $-29.4M | $-42.5M | $-52.4M |